Welcome to our dedicated page for Medical Mari news (Ticker: MJNA), a resource for investors and traders seeking the latest updates and insights on Medical Mari stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medical Mari's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medical Mari's position in the market.
Medical Marijuana, Inc. (MJNA) announced the appointment of Peter J.E. Verdegem, Ph.D., MSc, MBA, as Vice President for North America and German-speaking markets. Verdegem brings over 20 years of direct sales experience and a focus on health and wellness products. His role will involve driving domestic and international expansion and product development for the subsidiary, Kannaway®. The global CBD market is projected to reach $13.4 billion by 2028, which aligns with the company's growth goals under Verdegem's leadership.
Medical Marijuana, Inc. (OTC: MJNA) announced the hiring of Lennon Ledbetter as Vice President of Sales for its subsidiary, Kannaway®. Ledbetter is recognized as a leader in the direct selling industry with a proven track record of generating millions in revenue. His role focuses on expanding Kannaway’s domestic and international presence while recruiting top talent. Kannaway aims to continue innovating within the cannabis sector by providing high-quality CBD products and fostering opportunities for individuals in the growing cannabis industry.
Summary not available.
Medical Marijuana, Inc. (OTC: MJNA) has announced a partnership between its subsidiary, Kannaway, and The Por Grace Foundation. This collaboration aims to raise awareness about the benefits of cannabidiol (CBD) and to provide CBD products to families in need. Since its inception, Kannaway has donated over $2 million in CBD products. The Por Grace Foundation was established by the parents of a child with epilepsy to advocate for legal access to CBD in Mexico. The partnership seeks to break down barriers to access and support families in need of CBD treatments.
Medical Marijuana, Inc. (OTC: MJNA) announced that its subsidiary, Kannaway®, has expanded operations into Hong Kong following success in Japan. CEO Blake Schroeder highlighted the growing demand for high-quality cannabidiol (CBD) products as interest in hemp-derived CBD increases in the region. Kannaway® plans to host regional events to educate Brand Ambassadors about wellness benefits and financial opportunities. The company continues to be a pioneer in the cannabis industry, having developed a robust international market.
Medical Marijuana, Inc. (OTC: MJNA) has made headlines as its CEO Blake Schroeder discusses the hemp-based CBD industry's landscape in a recent Industry Era Magazine article. Schroeder emphasizes the company’s commitment to quality CBD products amid growing competition with lower-grade options. The article also highlights the company’s international expansion and partnerships for clinical studies in Mexico and Brazil, including a notable published study on drug-resistant epilepsy. MJNA has received import permits from multiple governments, solidifying its market leadership.
Medical Marijuana, Inc. (OTC: MJNA) reported strong financial results for Q2 2021, with net revenue of $9.6 million, up 8% QoQ. Net income soared by 86% to $7.0 million. The company also increased its cash position by 34% to $6.6 million. Gross profit was reported at $5.6 million, and net cash provided by operating activities reached $2.0 million, one of the highest in its history. CEO Blake Schroeder noted ongoing growth and expansion plans in international markets, highlighting both Latin American and Asian business momentum.
Medical Marijuana, Inc. (OTC: MJNA) announced record revenues for its subsidiaries HempMeds® Mexico and Kannaway® Japan in July 2021, marking their largest revenue months in history. The company's overall revenue also reached its highest since November 2020. CEO Blake Schroeder emphasized the company's ongoing commitment to success in the CBD and hemp industries, aiming to establish itself as a leading global cannabis company. According to Grand View Research, the global CBD market is projected to grow at a CAGR of 21.2%, reaching $13.4 billion by 2028.
Medical Marijuana, Inc. (OTC: MJNA) announced that its subsidiary, Kannaway®, has joined two leading hemp industry organizations in Japan: the Hokkaido Industrial Hemp Association and the Association for Japan Cannabinoid. This follows Kannaway®'s approval to distribute THC-free cannabidiol products in Japan since 2019. The global CBD oil market is projected to reach $5.3 billion by 2025, with significant growth in Asia-Pacific. Kannaway® aims to enhance its business internationally, emphasizing the expanding rights for Japanese citizens to access hemp products.
Medical Marijuana, Inc. (OTC: MJNA) announced the launch of a new product, broad-spectrum CBD-infused gummies, through its subsidiary HempMeds®. The gummies are gluten-free, vegan, available in lime, strawberry, and orange flavors, and each jar contains 1,200mg of CBD. CEO Raul Elizalde emphasized consumer feedback in the creation of these gummies, which feature high-quality broad-spectrum CBD instead of CBD isolate. The CBD gummies market is projected to grow at a CAGR of 30.7%, reaching USD 1.6 billion in size by 2028.